FHIR © HL7.org  |  Server Home  |  XIG Home  |  XIG Stats  |  Server Source  |  FHIR  

FHIR IG Statistics: FHIR Resources

ValueSets

28,490 resources

Source: Text:

By Version

By Authority

By Realm

 

Start Prev Rows 1200 - 1400 Next

PackageVersionIdentityName/TitleStatusFMMWGDateRealmAuthSource(s)
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1074Hemifacial spasm I10active2025-05ushl7icd
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1075Hemifacial spasmactive2025-05ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1076Spasmodic dysphonia SCTactive2025-05ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1077Physical therapy procedure SCTactive2025-05ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1078Occupational therapy SCTactive2025-05ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1079Hyperhidrosis SCTactive2025-05ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1080Hyperhidrosis I10active2025-05ushl7icd
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1081Hyperhidrosisactive2025-05ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1082Tic disorder I10active2025-05ushl7icd
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1083Tic disorder SCTactive2025-05ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1084Tic disorderactive2025-05ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1085Esophageal achalasia SCTactive2025-05ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1086Esophageal achalasia I10active2025-05ushl7icd
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1087Esophageal achalasiaactive2025-05ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1088ET propanolol or primidoneactive2025-05ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1089ET topiramate alprazolam or gabapentinactive2025-05ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.109CKD stage4above I10active2024-05ushl7icd
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1090Blephraospasm SCTactive2025-05ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1091Blepharospasm I10active2025-05ushl7icd
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1092Blepharospasmactive2025-05ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1093Strabismus SCTactive2025-05ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1094Strabismus I10active2025-05ushl7icd
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1095Strabismusactive2025-05ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1096Overactive bladder SCTactive2025-05ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1097Overactive bladder I10active2025-05ushl7icd
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1098Overactive bladderactive2025-05ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1099Movement disorders SCTactive2025-05ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.110CKD stage4above SCTactive2024-06ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1100Movement disorders I10active2025-05ushl7icd
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1101Movement disordersactive2025-05ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1102Lateral epicondylitis SCTactive2025-05ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1103Lateral epicondyltisis I10active2025-05ushl7icd
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1104Lateral epicondylitisactive2025-05ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1105Plantar fasciitis SCTactive2025-05ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1106Plantar fasciitis I10active2025-05ushl7icd
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1107Plantar fasciititsactive2025-05ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1108Cardiac CT SCTactive2025-05ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1109Cardiac CT CPTactive2025-05ushl7cpt
us.nlm.vsacR42.16.840.1.113762.1.4.1078.111CKD stage4aboveactive2024-06ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1111Cardiac CTactive2025-05ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1112Cardiac MRI SCTactive2025-05ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1113Cardiac MRI CPTactive2025-05ushl7cpt
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1114Cardiac MRIactive2025-05ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1115CT Angiography of Coronary Artery SCTactive2025-05ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1116CT Angiography of Coronary Artery CPTactive2025-05ushl7cpt
us.nlm.vsacR42.16.840.1.113762.1.4.1078.1117CT Angiography of Coronary Arteryactive2025-05ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.120Diabetic ketoacidosis SCTactive2023-07ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.121Diabetic ketoacidosisactive2023-07ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.146Long Acting Muscarinic Antagonists (LAMA)active2023-11ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.159conditions_COPD I10active2024-08ushl7icd
us.nlm.vsacR42.16.840.1.113762.1.4.1078.175Asthmaactive2025-05ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.184DigTx Virtual Reality Contraindications Visual Impairmentactive2023-07ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.186Beta blockers GDMT for heart failureactive2023-12ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.188medications_heart failureactive2024-12ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.197Blood (Serum and Plasma) Potassiumactive2023-11ushl7loinc
us.nlm.vsacR42.16.840.1.113762.1.4.1078.214Type 1 Diabetes Mellitus SCTactive2023-07ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.238MRA mineralocorticoid receptor antagonistsactive2024-10ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.244MRA Mineralocorticoid Receptor Antagonist Allergyactive2023-06ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.260UACR SCTactive2023-07ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.263Pregnancy I10active2023-11ushl7icd
us.nlm.vsacR42.16.840.1.113762.1.4.1078.281Statins Allergy SCTactive2023-03ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.282Statin Allergy Intoleranceactive2025-04ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.314relatedconditions_hyperlipidemia I10active2023-10ushl7icd
us.nlm.vsacR42.16.840.1.113762.1.4.1078.337Migraine I10active2023-03ushl7icd
us.nlm.vsacR42.16.840.1.113762.1.4.1078.34Blood pressure panelactive2024-04ushl7loinc
us.nlm.vsacR42.16.840.1.113762.1.4.1078.35Systolic Blood Pressureactive2024-04ushl7loinc
us.nlm.vsacR42.16.840.1.113762.1.4.1078.367Trandolaprilactive2024-12ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.369Candesartanactive2023-07ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.377Valsartanactive2023-07ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.397eGFRactive2025-03ushl7loinc
us.nlm.vsacR42.16.840.1.113762.1.4.1078.412Statin Moderate Intensityactive2024-08ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.415LDL Cholesterolactive2024-02ushl7loinc
us.nlm.vsacR42.16.840.1.113762.1.4.1078.43Urinalysisactive2024-02ushl7loinc
us.nlm.vsacR42.16.840.1.113762.1.4.1078.434Insulinactive2025-02ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.437TZD Thiazolidinedionesactive2025-05ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.438medications_T2DMactive2023-08ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.440relatedconditions_T2DM SCTactive2023-09ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.442Blood Glucoseactive2024-07ushl7loinc
us.nlm.vsacR42.16.840.1.113762.1.4.1078.459Liver canceractive2023-07ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.47ACE inhibitor allergy SCTactive2022-08ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.474Allergy to Tdap Vaccineactive2023-06ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.475Allergy to Td Vaccineactive2023-06ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.481medications_hypertensionactive2024-12ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.492Inhaled Corticosteroids Allergyactive2023-07ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.498Metformin AllergyIntolerance SCTactive2023-09ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.508Abdominal aortic imaging CPTactive2023-07ushl7cpt
us.nlm.vsacR42.16.840.1.113762.1.4.1078.517Hemoglobin A1cactive2024-03ushl7loinc
us.nlm.vsacR42.16.840.1.113762.1.4.1078.518Drug hypersensitivity I10active2023-07ushl7icd
us.nlm.vsacR42.16.840.1.113762.1.4.1078.519Drug hypersensitivity SCTactive2023-07ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.520Drug hypersensitivityactive2023-07ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.521Diabetic Kidney Disease I10active2023-07ushl7icd
us.nlm.vsacR42.16.840.1.113762.1.4.1078.523Diabetic kidney diseaseactive2023-07ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.524Chronic Hepatitis SCTactive2023-07ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.525Chronic Hepatitisactive2023-07ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.527OCS_Prednisoneactive2024-12ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.531Anti IgE Medicationsactive2023-07ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.532IL5 Antagonistsactive2023-07ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.533Mast cell stabilizers for asthmaactive2023-07ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.534Vasospastic disease I10active2023-08ushl7icd
us.nlm.vsacR42.16.840.1.113762.1.4.1078.535Vasospastic disease SCTactive2023-07ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.536Vasospastic diseaseactive2023-07ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.537Hemiplegic and basilar migraine I10active2023-07ushl7icd
us.nlm.vsacR42.16.840.1.113762.1.4.1078.538Hemiplegic and basilar migraine SCTactive2023-07ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.539Hemiplegic and basilar migraineactive2023-07ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.540Peptic ulcer disease I10active2023-07ushl7icd
us.nlm.vsacR42.16.840.1.113762.1.4.1078.541Peptic ulcer disease SCTactive2023-07ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.542Peptic ulcer diseaseactive2023-07ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.544Bleeding disorder I10active2023-07ushl7icd
us.nlm.vsacR42.16.840.1.113762.1.4.1078.545Bleeding disorder SCTactive2023-07ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.548Electronic cigarettes or Vapingactive2023-07ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.549Bleeding disorderactive2023-07ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.552Triptansactive2023-08ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.553CGRP receptor antagonistsactive2023-08ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.554Ditansactive2023-08ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.555Ergotsactive2023-08ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.556Migraine specific NSAIDsactive2023-08ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.557OTC migraine analgesicsactive2023-08ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.559medications_migraine_acuteactive2023-11ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.560relatedconditions_migraine I10active2023-08ushl7icd
us.nlm.vsacR42.16.840.1.113762.1.4.1078.561conditions_migraineactive2023-08ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.562relatedconditions_migraine SCTactive2023-08ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.563relatedconditions_migraineactive2023-08ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.564Triptan Allergy Intolerance SCTactive2023-08ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.565Triptan Allergy Intoleranceactive2025-04ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.566Ischemic bowel disease SCTactive2023-08ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.567Ischemic bowel disease I10active2023-08ushl7icd
us.nlm.vsacR42.16.840.1.113762.1.4.1078.568Ischemic bowel diseaseactive2023-08ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.573conditions_hyperlipidemia I10active2023-08ushl7icd
us.nlm.vsacR42.16.840.1.113762.1.4.1078.574conditions_hyperlipidemia SCTactive2023-08ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.575conditions_hyperlipidemiaactive2023-08ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.578PIM_Schedule Vactive2023-08ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.580PIM_Acarboseactive2023-09ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.582PIM_Dulaglutideactive2023-09ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.583PIM_Glimepirideactive2023-09ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.585PIM_Glucophageactive2023-08ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.587PIM_Glucovanceactive2023-08ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.588Glyburide PIMactive2023-08ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.590Alpha glucosidase inhibitorsactive2023-08ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.592Azotemiaactive2023-08ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.594Intolerance to ARB SCTactive2023-09ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.595ICS Lowactive2024-12ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.596ICS Mediumactive2023-08ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.597ICS Highactive2023-08ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.598Low Dose ICS Formoterolactive2024-05ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.600PIM_Vitamin B12 Level_LOINCactive2023-09ushl7loinc
us.nlm.vsacR42.16.840.1.113762.1.4.1078.601PIM_Vitamin B12 Level_CPTactive2023-09ushl7cpt
us.nlm.vsacR42.16.840.1.113762.1.4.1078.604PIM_Glyburideactive2023-09ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.605PIM_Pioglitazoneactive2023-09ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.606PIM_Semaglutideactive2023-09ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.607PIM_Linagliptinactive2023-09ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.609Macrolide_Azithromycinactive2023-08ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.61Secondary antihypertensivesactive2023-07ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.610Long Acting Beta Agonists (LABA) Non_Formoterolactive2023-11ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.612Wolff Parkinson White SCTactive2023-09ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.613Wolff Parkinson White I10active2023-09ushl7icd
us.nlm.vsacR42.16.840.1.113762.1.4.1078.614Wolff Parkinson Whiteactive2023-09ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.615medications_Asthmaactive2024-12ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.619ICS_LABA_LAMAactive2023-09ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.620Low Dose ICS_LABA_Non Formoterolactive2024-06ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.621Medium ICS_LABA Non Formoterolactive2023-11ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.623LAMA Allergy SCTactive2023-09ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.624LABA Allergy SCTactive2023-09ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.625BetaBlock NonCS Secondary Allergy SCTactive2023-09ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.626Eplerenone Allergy SCTactive2023-09ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.627Spironolactone Allergy SCTactive2023-09ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.628SGLT2 Inhibitors Allergy SCTactive2024-04ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.629PIM_Refill_Request_Antilipemics_LFTsactive2023-09ushl7loinc
us.nlm.vsacR42.16.840.1.113762.1.4.1078.630Angiotensin Receptor Neprilysin Inhibitor(ARNI) Allergy SCTactive2023-09ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.631Pneumococcal Vaccine Allergy SCTactive2023-09ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.632Meglitinides Allergy SCTactive2024-04ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.633DPP4i Allergy SCTactive2024-04ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.635Alpha_glucosidase inhibitors allergy SCTactive2023-09ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.636Glucagon_Like Peptide 1 Receptor Agonist (GLP1RA) Allergy SCTactive2023-09ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.637Insulins Allergy SCTactive2023-09ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.638TZD Allergy SCTactive2024-04ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.639T2DM_Medications Allergy SCTactive2023-09ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.642T2DM_Medications Allergy RXNORMactive2023-09ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.643T2DM_Medications Allergy SNOMEDactive2023-09ushl7sct
us.nlm.vsacR42.16.840.1.113762.1.4.1078.646T2DM_Medication Allergy Intoleranceactive2023-09ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.647Statins Allergy Intoleranceactive2023-09ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.649ACE Inhibitors Allergy Intoleranceactive2025-04ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.650ARB Allergy Intoleranceactive2025-04ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.652Long Acting Muscarinic Antagonists (LAMA) Allergy Intoleranceactive2023-09ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.653Long Acting Beta Agonists (LABA) Allergy Intoleranceactive2023-09ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.654BetaBlocker NonCS Secondary Allergy Intoleranceactive2023-09ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.656MRA Allergy Intoleranceactive2025-04ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.657Eplerenone Allergy Intoleranceactive2023-09ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.658Spironolactone Allergy Intoleranceactive2023-09ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.659SGLT2i Allergy Intoleranceactive2025-04ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.660Angiotensin Receptor Neprilysin Inhibitor(ARNI) Allergy Intoleranceactive2023-09ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.661Tetanus, Diphtheria, Pertusis (Tdap) Vaccine Allergy Intoleranceactive2023-09ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.665Tetanus toxoid, diphtheria (Td) Vaccine Allergy Intoleranceactive2023-09ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.666Human Papillomavirus (HPV) vaccine Allergy Intoleranceactive2023-09ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.667Herpes Zoster Vaccine Allergy Intoleranceactive2023-09ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.670Pneumococcal Vaccine Allergy Intoleranceactive2023-09ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.671Inhaled Corticosteroids(ICS) Allergy Intoleranceactive2023-09ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.672LABA(Formoterol only)active2023-11ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.674PIM_Tirzepatideactive2023-09ushl7rx
us.nlm.vsacR42.16.840.1.113762.1.4.1078.675GLP1RA Allergy Intoleranceactive2025-04ushl7vsac
us.nlm.vsacR42.16.840.1.113762.1.4.1078.676PIM_Diabetes_Testing_Suppliesactive2025-05ushl7cms